Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement

2005 ◽  
Vol 37 (6) ◽  
pp. 407-417 ◽  
Author(s):  
R. Caprilli ◽  
E. Angelucci ◽  
A. Cocco ◽  
A. Viscido ◽  
V. Annese ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Position Statement ◽  
Immunosuppressive Drugs ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Uso de probióticos na nutrição de cães com Doença Inflamatória Intestinal (DII) – uma atualização

2021 ◽  
Vol 4 (5) ◽  
pp. 75-87
Author(s):  
Cláudio Marcos Rocha-de-Souza ◽  
◽  
Ana Carolina Aor Zaqueu ◽  
Lívia Rodrigues da Cruz ◽  
Marcelo Gomes de Souza ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Weight Loss ◽  
Antibiotic Therapy ◽  
Inflammatory Bowel Diseases ◽  
Bowel Disease ◽  
Immunosuppressive Drugs ◽  
Intestinal Diseases ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Digestive Disorders

Canine Inflammatory Bowel Disease (IBD) is the term used to designate a group of chronic intestinal diseases, manifested by persistent or recurrent gastrointestinal signs. Known symptoms are vomiting, diarrhea, changes in appetite and weight loss. Treatment consists of a diet combined with antibiotic therapy and immunosuppressive drugs. It is currently known that changes in the microbiota profile can be used as way to prevent digestive disorders, since some probiotics offer benefits to patients with IBD, reducing symptoms and improving their immunity, however, can say that there is still no consensus regarding the recommendation of the use probiotics in inflammatory bowel diseases.

scholarly journals P243 Elevated presepsin levels are a marker of sepsis risk in patients with inflammatory bowel diseases receiving therapy of TNF-α blockers

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S286-S287
Author(s):  
O Knyazev ◽  
A Kagramanova ◽  
A Lishchinskaya ◽  
I Li ◽  
K Noskova ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Severe Disease ◽  
Clinical Status ◽  
Predictive Marker ◽  
Immunosuppressive Drugs ◽  
Low Risk ◽  
Moderate Risk ◽  
Tnf Α ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Abstract Background Sepsis is a severe disease characterized by a systemic inflammatory response syndrome (SARS) associated with infection. Sepsis is registered in 1–2% of all hospitalized patients. IBD patients receiving immunosuppressive therapy have a high risk of developing sepsis. Diagnosis of sepsis is based on internationally agreed criteria. Predicting the course and outcomes of sepsis is evaluated on the MEDS (Mortality in Emergency Department Sepsis) scale. Clinical studies of a new biomarker called presepsin have shown that it is a promising early and predictive marker of sepsis Aim to establish the role of presepsin as a marker of sepsis development in patients with inflammatory bowel diseases (IBD) receiving therapy with genetically of TNF-α blockers. Methods The clinical status of 128 IBD patients receiving of TNF-α blockers therapy (without immunosuppressive drugs) was evaluated in the Department of IBD. 68 patients with ulcerative colitis (UC) and 60 patients with Crohn’s disease (CD). Presepsin level (PSP) was determined in all IBD patients (100.0%). To stratify patients, the following criteria were used for baseline PSP levels (pg/ml): < 200 – very low risk of sepsis; - 200 - 300– low risk of sepsis; - 300 - 500– moderate risk of sepsis; - 500 - 1000 – sepsis; - ≥ 1000-severe sepsis, septic shock Results The distribution among 128 IBD patients receiving of TNF-α blockers by presepsin level was as follows: < 200 -75 (58,6%); - 200 – 300 – 34 (26,6%); - 300 – 500 – 19 (14,8%); - 500 - 1000 – 0 (0%); ≥ 1000 – 0 (0%). Of the 75 IBD patients receiving gibp and having a very low risk, none of the patients developed sepsis; of the 34 IBD patients with a low risk, one patient developed septicemia (2.9%). Among 19 patients with IBD with a moderate risk, the development of a septic condition occurred in 4 (21.0%) patients (HR-0.140, 95% CI 0.017 - 1.162; x2-2,800; p= 0.04997). Conclusion IBD patients receiving of TNF-α therapy, it is advisable to determine the level of presepsin in order to identify risk groups for the development of sepsis. Patients with IBD who receive of TNF-α therapy and have presepsin values in the range of 300–500 pg/ml have a significantly higher risk of developing sepsis.

scholarly journals Inflammatory Bowel Diseases: Focus on Therapy

2018 ◽  
Vol 24 (1) ◽  
pp. 9-14
Author(s):  
Tocia Cristina ◽  
Achim Anda Carmen ◽  
Alexandrescu Luana ◽  
Dumitru Eugen
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Inflammatory Bowel Diseases ◽  
Biologic Therapy ◽  
Immunosuppressive Drugs ◽  
Surgical Interventions ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Extraintestinal Complications

Abstract INTRODUCTION: Medical management of Inflammatory Bowel Diseases is complex and tailored to disease activity. The primary goal is the induction of remission and maintenance of remission with longterm prevention of disease progression. AIM: to describe current drug treatment practices in Inflammatory Bowel Diseases in Dobrogea. MATERIAL AND METHOD: The retrospective and descriptive study included 128 patients: group 1 = Crohn’s Disease (79), group 2 = Ulcerative Colitis (46) and group 3 = Unclassified Colitis (3). RESULTS: The phenotypic distribution was: 62% with Crohn’s Disease, 36% with Ulcerative Colitis and 3 patients with Unclassified Colitis. CROHN’S DISEASE: According to Montreal Classification, the majority of patients were diagnosed after 40 years (58%); the most frequent involvement was ileo-colonic (47%) and the most frequent phenotype was inflammatory (60%). 40% patients had intestinal complications and 7% had extraintestinal complications. 16.4% required surgical interventions. 67% were treated at some point with aminosalicylates, 44% with immunosuppressive drugs (thiopurines), 80% with corticosteroids for the induction of remission (inaugural flare) and 50% of them received again corticosteroidssteroids in the evolution of the disease, and 29% with biologic therapy. ULCERATIVE COLITIS: Most common location was left colitis in 47% cases. One patient had intestinal complications and no extraintestinal complications were reported in this group. No patients required surgical interventions. 82.5% were treated at some point with aminosalicylates, 37% with immunosuppressive drugs (thiopurines), 17% with corticosteroids and 11% with biologic therapy. UNCLASSIFIED COLITIS: In this group were not reported intestinal and extraintestinal complications and also no patient required surgical interventions. 2 patients were treated at some point with aminosalicylates, all patients were treated with immunomodulators and only one patient was administered biologic therapy. CONCLUSIONS: Particularities of Crohn’s Disease in our region are: widespread use of aminosalicylates, overuse of corticosteroids overtime, underprescribed biologic therapy.

Sign in / Sign up

Export Citation Format

Share Document